US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare ... With a portfolio of iconic brands, such as Allegra, Doliprane and Dulcolax ...

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business ... Opella, which houses brands including Allegra, generated sales of $5.7 billion ...

It also owns the antihistamine brand Allegra and the laxative Dulcolax. "Together, CD&R and Sanofi will support Opella's growth strategy as a pure-play, global and fast-moving consumer health care ...

Sanofi first telegraphed plans for a potential consumer health separation last October ... the company is known for popular household brands like the allergy med Allegra, Icy Hot for muscle ...

With a portfolio of brands, such as Allegra ... reportedly raised its bid for Sanofi’s consumer health division by around 200 million euros ($217.12 million). While CD&R has emerged as the ...

Opella employs 11,000 people globally and sells popular French pain medicine Doliprane, as well as brands ... Sanofi, which said a year ago it was reviewing separation scenarios for its consumer ...

Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a ...

Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra and Dulcolax. Sanofi SA SNY and private equity Clayton Dubilier ...